A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer

Trial Profile

A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Ralimetinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Mar 2016 Results (n=40) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 18 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 17 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top